Table 5 Study description, recruitment outcomes reported by researchers and two derived performance metrics
Study name | Region(s) Involvedc | Study Inclusion & Exclusion Criteriac | Target No. of Participants | No. Received from SHARE | No. Recruited through SHARE | No. Recruited through Other Recruitment Means | Percentage Provided and Recruited | Percentage Fulfilled |
|---|---|---|---|---|---|---|---|---|
Ω | -f | -f | 20 | 30 | 20 | 0 | 66.7 | 100.0 |
V | West | Inclusion: • Age: 20–39 Exclusion: • Insulin dependent diabetes • Diseases of the Nervous System 1 • Diseases of the Nervous System 2 • Congenital malformations of the nervous system • Inability to give informed consent • Mental retardation • Alzheimer’s Disease • Other degenerative diseases of the CNSd, not elsewhere specified • Other degenerative disorders of nervous system in diseases classified elsewhere • myotonic dystrophy or other muscular dystrophy • family history of myotonic dystrophy and never tested • Severe concurrent medical condition, e.g. cardiac failure or respiratory failure • Contraindications to MRIe • History of major head trauma with loss of consciousness greater than a few minutes or with significant medical sequelae | 60 | NAd | 8 | 48 from clinical database of patients with myotonic dystrophy; 12 controls recruited from patients’ families | /e | 13.3 |
NAd | -f | -f | 20 | NAd | 10 | 10 | /e | 50.0 |
R | East | Inclusion: • Aged 60–85 • Fluent in English • Able to read • Reliable study partner/informant Exclusion: • Dementia or any degenerative brain disorder • Brain disease • On cholinesterase inhibitors and/or memantine • Receiving daily medications with the potential to affect cognition such as sedatives, pain medications, or anticonvulsants within 30 days • Familial autosomal dominant Alzheimer’s disease or other familial dementing diseases • Uncontrolled or untreated thyroid problems • Clinically significant vitamin B12 or folic acid deficiency • Chromosome21trisomy • History within the past 2 years or current diagnosis of significant psychiatric illness • History within the last 5 years of a serious infectious disease affecting the brain or head trauma resulting in protracted loss of consciousness • Contraindications for MRI • Major surgery, requiring general anaesthesia within 8 weeks or has not recovered • Exposure to ionizing radiation • Learning disability • Currently participating in any interventional studies • Currently participating in non-interventional study that involves exposure to radiation or neuropsychological testing • History within the last 5 years of any type of cancer • Currently on regular Vitamin B injections • Currently taking anti-seizure medications • Currently taking co-codamol or dihydrocodeine • Currently taking opioids • Currently taking benzodiazepines • Stroke • Blindness • Deafness or significant hearing impairment • Seizures | 250 | 650 | 152 | 375 | 23.4 | 60.8 |
E | Southeast | Inclusion: • Age: 40–90 • Healthy Exclusion: • Diseases of eye and adnexa • Inflammatory diseases of the central nervous system • Systemic atrophies primarily affecting the central nervous system • Extrapyramidal and movement disorders • Other degenerative diseases of the nervous system • Demyelinating diseases of the central nervous system • Vascular syndromes of brain in cerebrovascular diseases • Cerebral palsy and other paralytic syndromes Stroke, not specified as haemorrhage or infarction | 150 | 156 | 84 | 3 friends of people who had agreed to help during previous study | 53.8 | 56.0 |
Y | West and Southeast | Inclusion: • Diagnosis of F20.0, F20.1, F20.2, F20.3, F20.5, F20.9 • 25–55 years of age • Body Mass Index (BMI) of 18 to 30 kg/m2 • A total body weight 50–100 kg • Stable Antipsychotic medication for 1 month prior to visit 1 Exclusion: • An existing neurological disorder • Metal implants in body parts • Pregnancy • Psychiatric hospitalization over 6 months before visit 1 • Change of medication ≤1 month prior to visit 1 • Patients who are currently taking clozapine • Current substance abuse, including cannabis | 30 | 30–50 | 0 | 2 | 0 | 0 |
B | Southeast | Inclusion: • Female • Age: 18–50 • Complaint of HMBb • Prescription for tranexamic acid or mefenamic acid Exclusion: • Cancer • Severe Coagulation disorder • Diabetes • Hysterectomy | 108 | 28 | 6 | 85 through NHS Menstrual Problem; 38 through GP letter by SPCRNa or leaflet given by GP; 20 through poster in clinical area, NHS/University staff website; 27 from Facebook adverts | 21.4 | 5.6 |
NAd | /e | /e | 350 | NAd | NAd | NAd | /e | /e |
I | Southeast | Exclusion: • Age: ≥18 years old • men or post-menopausal women (women with no periods for at least 12 months or having a surgical menopause) • Hypertension Exclusion: • Ischaemic heart disease • Cardiac failure • Cerebrovascular disease • Liver impairment disease • CKD stage 3–5 • Overdose or suicidal ideation • Weight less than 55 kg • Chronic pain requiring treatment • with a known allergy to paracetamol • concomitant use of NSAIDs, oral anticoagulants or corticosteroids | 110 | 37 | 7 | 100 through SPCRN; 97 through ABPMb clinics | 18.9 | 6.4 |
Σ | -f | -f | 12 | 92 | 10 | 13 | 10.9 | 83.0 |
Φ | -f | -f | 100 | 0 | 0 | 103 | 0 | 0 |
M | Southeast | Inclusion: • 65 years old or older • Residents of Edinburgh or surrounding areas (including Lothians) Exclusion: • Have a history of dementia • Stroke • Other neurological disorders • Traumatic brain injury • Major psychiatric disorders | 300 | NAd | NAd | NAd | /e | /e |